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Project Abstract: 
 
The Coalition of Kentucky Health Professionals Against Substance Abuse (CKHPASA) 
is a professional organization uniting members of the various health professions against 
a rising tide of substance abuse in the state of Kentucky. In 2013, Kentucky ranked 3rd 
in the United States for highest number of drug overdose fatalities. Previously under the 
scourge of the prescription opioid epidemic, the state of Kentucky is now seeing rising 
numbers of overdose deaths related to heroin use, which is an opioid that works 
similarly to morphine and prescription pain medications.  
 
Naloxone is a life-saving antidote for opioid related overdoses and evidence has shown 
dramatic decreases in overdose related deaths as access to at-home naloxone 
increases. Senate Bill 192, signed into law in 2015, grants Kentucky pharmacists the 
ability to dispense naloxone to patients requesting it at their pharmacy without an 
expressly written physician’s prescription. The pharmacists must be certified to 
dispense naloxone by the Kentucky Board of Pharmacy and enter into a collaborative 
care agreement with a local physician to be capable of dispensing naloxone in this 
manner.  
 
In eastern Kentucky in rural Appalachia, access to physicians, emergency services, and 
hospitals is diminished compared to suburban and urban areas of the state. In these 
disparate communities, at-home naloxone obtained at the local pharmacy will reduce 
overdose related mortality and morbidity by increasing access to the antidote and 
overcoming barriers to timely emergency response. In the context of this grant, 
CKHPASA will utilize board-certified pharmacists in collaborative care agreements with 
local physicians to provide addicts and their loved ones in Bell, Breathitt, Floyd, Harlan, 
and Perry counties with access to naloxone as a harm reduction strategy.  
 
These five counties were among the highest ranked in overdose death rate per capita in 
the state of Kentucky in 2013 and are the focus of this intervention. This intervention is 
modeled after two successful Overdose Education and Naloxone Distribution (OEND) 
programs. It will provide naloxone via auto-injector to addicts or their loved ones, the 
necessary education to successfully administer the naloxone in the event of an 
overdose situation, and information on resources in the area to assist the opioid addict 
on their journey toward lasting sobriety along the Transtheoretical Model of Change. 
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A. TARGET POPULATION AND NEED 
For many years, Kentucky has been near the top of the national list for drug 
overdose deaths. In 2013, Kentucky ranked third in the nation for drug overdose deaths: 
a staggering 23.6 per 100,000 persons succumbing to fatal drug overdose. This figure 
has quadrupled since 1999 and reflects a well-documented prescription drug epidemic.1 
Since the transition to heroin from prescription painkillers in Kentucky, heroin overdose 
deaths have skyrocketed, jumping 55% between 2012 and 2013 and now accounting 
for 31.9% of all overdose deaths in the state.2,3 
 Although the greatest number of overdose 
deaths occur in Kentucky’s largest population 
centers, including Louisville (Jefferson County),  
Lexington (Fayette County), and Northern 
Kentucky (Kenton, Boone, and Campbell Counties) many of the 
hardest hit counties per capita are much more likely to be rural and in Appalachian-
designated counties in eastern Kentucky. In 2013, the counties with the most 
devastating burden of overdose deaths per capita included Bell (93.2 per 100,000), 
Breathitt (44.3), Floyd (43.9), Perry (42.8), and Harlan (42.1).3  
The Kentucky General Assembly passed Senate Bill 192 in 2015 as a response 
to the burgeoning statewide heroin epidemic. The bill, signed into law by then-governor 
Steve Beshear on March 25, 2015, contained multiple provisions targeting heroin 
abuse. In addition to stricter penalties for drug traffickers and a shifting focus from 
imprisonment to treatment for addicts, these provisions were also permitted pharmacists 
to dispense naloxone, which a life-saving opioid antidote, without a prescription.4,5 
County Overdose Deaths Per 100,000 
Bell 93.2 
Breathitt 44.3 
Floyd 43.9 
Harlan 42.1 
Perry 42.8 
Statewide 23.8 
Table	1	
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Naloxone may be requested by an addict or their loved ones to keep on hand in the 
event of an accidental overdose.6 Nowhere will this new provision of SB 192 be more 
helpful than in eastern Kentucky. In particular, this intervention focuses on the five 
counties with the highest rates per capita of overdose related death: Bell, Breathitt, 
Floyd, Perry, and Harlan. 
 In addition to the staggering per capita overdose death figures, the counties 
listed above are also grappling with extraordinary poverty rates. Bell County, which also 
topped the per capita overdose list, is nearly double the statewide poverty rate (see 
Table 2). The other counties in highlighted in the proposed intervention did not fare 
much better, and all of them exceed 
the 18.8% statewide poverty level.7  
These poverty rates correlate to the 
unemployment rate, with all five 
counties exceeding the statewide 
unemployment rate of 5.6%. In particular, Harlan County, which has been acutely 
affected by the changing coal 
economy, has an unemployment rate 
more than double that of the 
statewide average, at an astounding 
12% (see Table 3).8 
All five counties also are underserved with regard to mental health care access. It 
is well documented that many individuals seek drugs and alcohol as a coping 
mechanism for untreated mental illness. Recent epidemiologic studies have shown that 
Table	2	
Table	3	
County Poverty Rate 
Bell 35.7% 
Breathitt 33.9% 
Floyd 30.6% 
Harlan 30.5% 
Perry 26.9% 
Statewide 18.8% 
County Access to Mental Health Care (Persons 
in County : Number of Providers) 
Bell 6971:1 
Breathitt 847:1 
Floyd 159:1 
Harlan 4750:1 
Perry 180:1 
Statewide 621:1 
Table	4	
County Unemployment 
Rate 
Bell 9.2% 
Breathitt 9.4% 
Floyd 9.1% 
Harlan 12.0% 
Perry 8.5% 
Statewide 5.6% 
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between 30 and 60 percent of substance abusers are also determined to have a 
comorbid mental illness.9 In Harlan and Bell Counties in particular, for every individual 
mental health provider, there are thousands of residents in need of mental healthcare.10  
All five counties are more decidedly rural than the remainder of the state, and this 
plays an important role in responding to and treating an overdose, where every second 
counts. Rural communities face a number of barriers in access to care, not least of 
which is the considerable distance to the nearest Emergency Medical Services (EMS) 
station. Once EMS arrives and a 
dose of naloxone is administered, 
the victim will likely have to be 
taken to a hospital and stabilized. 
Depending on the half-life of the 
opiate that the victim ingested, they may be given additional doses of naloxone in the 
hospital. For many residents in the most remote parts of these counties, hospitals are 
often even further away. The longer the travel time, the higher the risk of complications. 
In these situations in particular, having access to and administering naloxone while 
waiting on first responders to arrive on the scene could mean the difference between a 
full recovery and severe and lasting complications, or in the worst cases, death.10    
 In addition to disparities in mental health care access and the complications that 
rurality adds to reliable EMS transportation, the five highlighted counties are designated 
Health Professional Shortage Areas (HPSA) for primary care. A HPSA denotes that 
within this region of Kentucky there are not enough primary care physicians to 
adequately serve the population at risk. Due to the patient burden most primary care 
County Percent of Population in Rural Areas 
Bell 62.5% 
Breathitt 83.9% 
Floyd 81.5% 
Harlan 54.2% 
Perry 74.1% 
Statewide 41.6% 
Table	5	
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physicians in the area face, and the relative distance from these counties to larger 
population centers with more advanced healthcare services, this provides naloxone-
certified pharmacists an unprecedented avenue to advocate for their patients.11  
It should be noted that there are other resources besides pharmacies available in 
these communities where target populations can access naloxone. All five counties 
have health departments that may also dispense naloxone and physicians that can write 
prescriptions for it. There are also a number of grassroots organizations in the area 
working to provide patients with educational materials pertaining to the planned 
intervention. However, it is the position of the Coalition of Kentucky Health 
Professionals Against Substance Abuse (CKHPASA) that these resources by 
themselves are still inadequate in responding to this crisis.  
Unlike most health departments and physician’s offices whose office hours are 
restricted to daytime and weekday hours, pharmacies provide much greater access to 
care. As we have shown, it is important that when the need arises for a naloxone kit, 
they should be as widely available as possible—not just available during the traditional 
9am-5pm weekday business hours. By offering this additional resource of naloxone 
distribution in these communities, we will reach more people than the current resources 
are able to reach, thus broadening the availability of this overdose antidote in the 
community.  
All five counties within the intervention are members of the Appalachian High 
Intensity Drug Trafficking Area (HITDA) as established by the Office of National Drug 
Control Policy. HITDAs represent areas where a large amount of drug related activity is 
happening and where law enforcement and other agencies can best make an impact—
OEND	BY	BOARD-CERTIFIED	PHARMACISTS	IN	FIVE	EASTERN	KY	COUNTIES																																																		6	
	
these counties are part of what has been designated as a “critical” region for drug use 
and trafficking.12  
Survey data from a recent State Health Issue poll showed that 9% of all 
Kentuckians and 15% of all Kentuckians 18-29 know someone who is addicted to 
heroin2, and Centers for Disease Control and Prevention (CDC) data suggest 5.2% of 
Kentucky high-school students use heroin.13 Given that this is statewide data and the 
counties in our intervention have overdose death rates that are twice the state level, and 
they are very geographically and socially close-knit communities,  
we believe it is possible that 30% or higher of our target 
population knows someone who uses heroin. However, 
because these people may know the same addict or 
addicts and because the persons administering 
naloxone in the event of overdose are more likely to be close friends or 
relatives rather than casual acquaintances, the goal of this project is to reach 10% of 
the total population of the five intervention counties annually. The total population of all 
five counties is 135,055.14 Therefore, we would like to distribute naloxone kits to at least 
1,350 people annually over the course of the three years of program implementation. 
 We will recruit patients to our program using a multi-modal mass media 
campaign. Print advertising will take place in all of the local newspapers, potentially with 
feature stories explaining the program within them. Flyers will be distributed at local 
businesses and churches. Due to the increasing prevalence of social media, a 
Facebook page will be set up by the Program Director to help recruit young people in 
particular to the project. We believe this connection is key, as young people are one and 
County Total Population (2014 est.) 
Bell 27,778 
Breathitt 13,409 
Floyd 38,108 
Harlan 28,163 
Perry 27,597 
Total 135,055 
Table	6	
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a half times as likely to know someone who abuses drugs as other adults (15% versus 
9%). Small town life revolves around the gathering spots for community members, so by 
targeting advertising in those locations, by utilizing print media, and by bringing in the 
youth through social media, the majority of the population of these communities will be 
aware of the project’s presence and will be able to find out more details in community 
forums held at the library or by calling a toll-free number to reach the CKPHASA. 
 Both those who abuse opioids themselves and are addicted as well as non-
addicted family members will be targeted. We think that this will increase reach of the 
program as it will cover two of the more common scenarios of drug use. The first is 
alone in their home, which increases direct need for a caregiver to have access, as the 
addict can’t administer their own dose of naloxone. The second is in a group setting with 
other addicts, where the addict could obtain the kit for themselves or for the benefit of 
the group. 
 Population data will continue to be monitored on an ongoing basis for changes in 
social determinants of health, overdose death rates, and other contributing factors to the 
high per capita prevalence of overdose. Continuous monitoring of the factors that make 
these communities ideal target factors will ensure our program continues to align with 
changing community needs. 
B. PROGRAM APPROACH 
 Although the first pharmacist protocols for distribution of naloxone without a 
prescription (generally through collaborative care agreements [CCAs] set up in 
conjunction with local physicians) are a relatively new phenomena in the United States, 
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there is growing body of evidence to suggest that getting naloxone into the hands of lay 
people saves lives. A 2012 survey published in Morbidity and Mortality Weekly Report 
(MMWR) documented that an estimated 53,032 people had received training in 
overdose prevention and administration of naloxone through 188 community-based 
programs in 15 states and Washington DC. The programs received more than 10,000 
reports of successful overdose reversals through administration of the naloxone by 
individuals who had received training. Ten thousand successful overdose reversals is a 
significant number of lives saved, even if some of the 10,000 are “repeat consumers” 
who have survived multiple overdoses.15 
 Naloxone (Figure 1) is a potent competitive µ-opioid receptor antagonist that is 
used to block the effects of opioids in the body, particularly in overdose situations. 
When naloxone is administered to someone undergoing an overdose, it will compete 
with the opioids present in the body for binding at µ-
opioid receptors in the central nervous system. Because 
of their high affinity for the receptor, the naloxone will 
prevent the action of the opioid causing overdose (Figure 
2) and thus stop the symptoms of overdose like 
respiratory depression and depressed heart rate.16 
 Additionally, as naloxone is a competitive antagonist and has nearly no agonist 
properties, when it binds to µ-opioid receptors 
it elicits little to no action itself—it is only 
“active” in the presence of other opioids. This 
																			Figure	1	
																																																				Figure	2	
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concept is key for those keeping or potentially utilizing naloxone in the home, because 
in the event of accidental use of the product by a child or someone without opioids in 
their system, the drug is essentially benign and poses no serious risk.16 
 When administered intravenously, naloxone works to relieve the symptoms of 
overdose within two minutes. When administered intramuscularly, naloxone works to 
relieve symptoms of overdose within five minutes. When naloxone kits are sent home, 
they are typically for intramuscular use, or more frequently, intranasal use. Intranasal 
naloxone works almost as quickly as intravenous administration. The intranasal dose is 
usually contained in a prefilled single-dose syringe with a mucosal atomizer that often 
must be screwed into place before the dose is administered in the nose.16  
 Perhaps the most well-researched program with outcomes that show the 
evidence of the efficacy of community-based Overdose Education and Naloxone 
Distribution (OEND) programs is a time-series analysis conducted following 
implementation of OEND programs in Massachusetts. The researchers conducted an 
interrupted time series analysis of annual opioid related rates of overdose fatalities and 
utilization of acute care hospitals comparing communities and years where OEND was 
implemented with those where it was not. Researchers included the 19 communities in 
Massachusetts with five or more opioid related fatal overdoses in each year from 2004 
to 2006, the two years prior to the implementation of OEND in Massachusetts. Training 
took place through six public health agencies in the state and was based on evidence-
based curriculum developed by the Harm Reduction Coalition and the Chicago 
Recovery Alliance.17 
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 In the Massachusetts OEND program, implementation was categorized in two 
ways. The first was based on median cumulative enrollment rate and from that, three 
groups were formed: groups with community-year strata that indicated no 
implementation, those below the median (low implementers), and those with enrollment 
rates above the median (high implementers). The second method involved determining 
if absolute population density of enrollment was associated with overdose rates. 
Communities were placed each year into three categories based on cumulative 
enrollment rate levels of no implementation, 1-100 per 100,000 population and >100 per 
100,000 population.17 
Even after adjustment for 
potential confounders such as 
demographics and substance abuse 
treatment utilization, rates of fatal 
overdose were 27% lower with low 
implementation communities and 
46% lower with high implementation communities of the OEND. Among the 19 
communities included in the study, 2912 individuals were enrolled in OEND programs 
over a three year period and 327 rescue attempts made using kits obtained from the 
program. Naloxone was successful in 98% of the rescue attempts, and the instances 
where it was not, the overdose victim received care from EMS and survived. This 
indicates the importance of the education component in recognizing the symptoms of 
overdose so that EMS was notified quickly enough to be impactful when intranasal 
naloxone administration failed.17  
Figure	3 
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There are three types of OEND programs with various levels of evidence 
supporting the efficacy of their implementation. The first type, which has been in 
existence the longest and has the largest body of evidence supporting it, is the Initial 
Public Health Model. This model targeted the high-risk addict only and offered OEND in 
environments like needle exchanges. The second type is the Expanded Public Health 
Model, which expands to target “bystanders” in addition to the addict—loved ones, 
friends, family, etc. The Massachusetts OEND program is an example of the Expanded 
Public Health Model. The final type is the Health Care Model, which involves distribution 
of naloxone by health care systems.18 
Pharmacists have an obligation to educate their patients on safe use of opioid 
medications—including those persons who use high doses of licit opioids daily who are 
also at risk of overdose. Part of opioid safety includes harm reduction that would come 
from those patients using opioids both licitly and illicitly being educated on the benefits 
of having naloxone on hand, and their caregivers being made aware of the signs of 
opioid overdose and instructed on how to administer naloxone. This education 
component already exists within the compulsory counseling offer pharmacy staff must 
make with each prescription purchase.20 Because of their extensive knowledge about 
medication and training in patient consultation, pharmacists are an ideal resource for 
dissemination of OEND in a Health Care Model. 
One of the first states in the United States to begin supplying naloxone through 
pharmacists in CCAs with physicians was Rhode Island. In response to Rhode Island 
having the highest overdose death rate per capita in the country at the time of the 
initiation of the program in 2011, the Rhode Island Board of Pharmacy approved a pilot 
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program in five Walgreens pharmacies in locations with high prescription opioid 
overdose mortality. After the pilot was completed, and in response to a growing problem 
with fentanyl overdose, the program spread to all Walgreens in the state and any other 
interested pharmacies. The Office of National Drug Control Policy has recognized this 
implementation of the OEND Health Care Model in Rhode Island as a leading public 
health-commercial collaboration, and an important distribution model for naloxone to 
address overdose risk in the community. While neighboring states reported significant 
increases in overdose related deaths between 2013 and 2014, Rhode Island’s number 
of deaths increased only minimally.20 
There are limitations acknowledged in both the Massachusetts and Rhode Island 
studies. Firstly, overdose survival based on International Classification of Diseases 
(ICD) codes at the hospital require that those codes are properly documented by 
various hospital staff, and either neglect to classify or misclassification could have 
altered those success numbers. Additionally, in any given year overdose could occur in 
clusters—a “bad batch” of heroin laced with another drug could spur more overdose 
deaths and those numbers would inaccurately reflect typical overdose rates for the 
area. Particularly in Massachusetts, successful reversals were mainly obtained through 
self-report back to the program, so these numbers have the inherent issues that come 
with data derived from self-report methods. The Rhode Island study in particular 
acknowledge differences in insurance reimbursement among the different types of 
naloxone and how that could limit the program’s effectiveness. 
Adapting programs to suit your area’s need is Step 4 of RAND’s Getting to 
Outcomes and we think this is a pivotal step in this community and for this problem.21 It 
OEND	BY	BOARD-CERTIFIED	PHARMACISTS	IN	FIVE	EASTERN	KY	COUNTIES																																																		13	
	
is with this in mind that we propose Opportunities for Distribution of Naloxone in Area 
Pharmacies in Eastern Kentucky (OD-NAP EKY), a program that will blend the evidence 
basis of the Massachusetts Expanded Public Health Model OEND with pharmacist-
dispensed naloxone in the Health Care Model from Rhode Island that was itself a 
“public health-commercial collaboration.” With the exception of the Rhode Island study, 
there are less instances of the efficacy of this model in community pharmacy based 
distribution because it is a new frontier in health care.  
Based on the data of the reach and success of the Massachusetts OEND 
program as well as the Rhode Island program in target those areas with higher rates of 
overdose and then subsequently decreasing those rates, we are confident that the 
adaptations of these programs will meet the needs as previously defined in this 
community and are a good fit for the implementation setting. We also believe that our 
collective organization’s presence in every county in Kentucky indicates that we have 
the capacity to make these programs work seamlessly within the target populations. 
The Massachusetts OEND put a strong emphasis on general education about 
recognizing overdose and also knowledge and self-efficacy in naloxone administration 
in the bystander population—which are crucial in a low health literacy population like our 
target population. General literacy is an issue in all of these counties, with a large 
percentage of adults scoring as “below basic” level of prose literacy, which means they 
could only interpret small pieces of uncomplicated written information.22  
County % Adult Population with 
“Below Basic” Literacy 
Bell 18 
Breathitt 17 
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With this in mind, OD-NAP EKY will tackle 
the issue of low health literacy by adapting the 
Massachusetts OEND program and the Rhode 
Island OEND program to switch from intranasal naloxone administration to naloxone 
delivered by auto-injectors. Intranasal administration often requires 
attaching a nasal actuator to a prefilled syringe, which can be 
complicated, and then proper delivery to the nasal mucosa, which may be challenging.  
Evzio®, the first auto-injector approved by the Food and Drug Administration 
(FDA), is a pocket-sized and portable dispensing device designed to administer a single 
dose of naloxone intramuscularly. The needle is housed within the device and is never 
exposed to the person administering the dose. The injection can even be administered 
through clothing. Once the outer case is taken off of the Evzio® device, the device 
begins to speak directions to the person administering the dose. First, it instructs them 
to prime the device for administration by removing the cap that covers the needle’s 
trajectory. Then, it instructs them to place the auto-injector on the overdosing victim’s 
outer thigh and press down hard. Once this happens, the needle is depressed down into 
the skin and the device begins a five second countdown. After the countdown 
completes, the needle retracts and the person administering the dose is instructed to 
remove the device and return the cap and outer case.23 
One main concern with the Evzio® injector has been that the small print on the 
device will not be helpful if a person is deaf or hard of hearing and cannot hear the 
directions as the device is speaking them. Kaléo Pharmaceuticals, which manufactures 
Evzio®, has larger leaflets that detail the administration process—complete with 
Floyd 15 
Harlan 18 
Perry 17 
Statewide 12 
Table	7	
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pictures—that we will include in the naloxone kit specifically for our deaf and hard of 
hearing patients. Having pictures of the actual administration process will also benefit 
our other patients as well by helping to increase self-efficacy by being able to visualize 
what they are to do.23 
 There will be five outreach points (one per county) when 
implementing our program, OD-NAP EKY. Each 
of those points will have a board-certified 
pharmacist to lead the pharmaceutical 
piece of program implementation at the independent pharmacies they manage in that 
county. The first will be in Floyd County (county seat of Prestonsburg) and sits slightly 
isolated from the other four counties. The pharmacist-in-charge at Cooley Apothecary in 
Prestonsburg will lead the transition in Floyd County. The area covered by this outreach 
point is denoted in red on Figure 4. 
 The second and third outreach points will cover patients in Breathitt and Perry 
Counties. This region is denoted in green on Figure 4. The county seat of Perry County 
is Hazard, Kentucky. The pharmacist-in-charge at the Medicine Shoppe in Hazard will 
begin outreach for that community.. The pharmacist-in-charge at the Jackson 
Apothecary in Jackson, Kentucky, the county seat of Breathitt County, will lead our 
program implementation there.  
 The fourth and fifth outreach points will cover patients in Bell and Harlan 
Counties. This region is denoted in blue on Figure 4. Our basis of operation for Bell 
County will fall to the pharmacist-in-charge at the Walters Pharmacy Shoppe in 
Middlesboro, the largest city in Bell County. She will be joined in our program by the 
Figure	4 
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pharmacist-in-charge at Donnell’s Pharmacy in Baxter, which sits just outside of the 
county seat of Harlan in Harlan County.  
 At our five pharmacies, all pharmacists and all staff will be required to go through 
sensitivity training. This is so patients coming in to request naloxone will not be 
stigmatized or treated poorly because of their addictions, nor will the Health Insurance 
Portability and Acountability Act (HIPAA) be violated. HIPAA is an act passed by the 
United States Congress and signed into law in 1996 that protects patient information 
from unlawful dissemination.24 The biggest concern for HIPAA violation because these 
are small towns is that pharmacy staff may either accidentally or maliciously tell other 
members of the community that another individual was seen at the pharmacy obtaining 
a naloxone kit. Not only is this a violation of that individual’s right to privacy under 
HIPAA, but may cause additional stigma or duress. Therefore, it is crucial that all staff 
know that HIPAA must be followed to the letter and strict reprimand will be imposed on 
those who do not follow these requirements, including a minimum of immediate 
termination of employment upon the conclusion of an investigation or harsher 
punishment if such punishment for HIPAA violation is already in the employee manual 
at an individual pharmacy.  
For all patients coming in to request naloxone, be they addicts themselves or the 
loved ones of addicts, training will be provided on how to administer naloxone, the 
existence of Good Samaritan laws, and the procedure following initial naloxone 
administration to reverse overdose. With regard to administration procedure, the 
pharmacist will employ the teach back method, wherein the patient is instructed to 
explain back to the pharmacist what they have learned. This will ensure that that the 
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patient understands procedure in its entirety and allows incorrect responses to be 
corrected immediately. 
In particular, it is crucial that the person receiving the kit is made aware of the 
changes Senate Bill 192 made to KRS 218A.133. In particular, that they cannot be 
prosecuted for their good faith administration of naloxone to the overdosing patient; and 
secondly, that no arrests may be made if EMS and/or police come to the premises on 
an overdose related call. Even if everyone else in the room is in possession of drugs 
and/or paraphernalia, as long as they stay until the overdose patient receives treatment, 
they will not be charged with anything. There are a few exceptions to this rule—if the 
persons with the overdose patient are running from existing warrants, or if there is 
existing evidence outside of the overdose situation in which to charge them, for 
example.25 This information will be given verbally, but also distributed in print form with 
dispensed prescriptions should the patient or loved one want it written down for easy 
recall later.  
Additionally, accompanying the kits of information that are given with each 
dispensed naloxone prescription will be resources for additional services beyond the 
scope of this project that aim to assist the addict in addressing their addiction and 
underlying problems. We will give contact and program information for Karen’s Place, a 
women’s treatment facility in Louisa, Kentucky and Layne’s House, a co-ed treatment 
facility in Pikeville, Kentucky. We will also include information on local Suboxone® and 
methadone maintenance clinics and/or physicians who provide these services. Part of 
the criteria for being included on this list of clinics is that the sites use a trauma-informed 
approach. 
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Information on access to local Department of Community Based Services 
(DCBS) offices will be provided to encourage those without health insurance to apply for 
Medicaid. Information will also be provided on local homeless shelters, crisis centers, 
and food banks. With these resources, it is understood that counseling provided by the 
pharmacist with dissemination of this literature will be considered a referral for services. 
If utilizing one of the listed services, when patients are asked what entity referred them 
to that service, they will be encouraged to name the referring pharmacy. While our goal 
with this program is to eliminate needless overdose deaths in the area, ideally a 
decrease in drug use in the area would decrease the emergent need for our services. A 
detailed logic model which contains information regarding these inputs and activities, in 
addition to the outputs and outcomes of this program can be found in Appendix A.  
 The five pharmacies mentioned will begin dispensing naloxone kits on January 1, 
2017. This allows time for all staff pharmacists to obtain naloxone certification, product 
to be ordered, and publicity for the new program to be generated starting June 1, 2016. 
Staff pharmacists will be encouraged to take the University of Kentucky College of 
Pharmacy’s course taught by Dr. Mimi Marquez, a member of the project team. Upon 
completion of the course, they will be able to apply for their certification from the 
Kentucky Board of Pharmacy. All pharmacy staff in each of the five pharmacies will 
attend sensitivity training by December 31, 2016. Additionally, coordination will be made 
with all local public libraries and schools to start placing our community education 
components onto their calendars beginning June 1, 2016. A more detailed analysis of 
the planning phase, and goals for implementation can be found in the attached Work 
Plan (see Appendix B). 
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 Fidelity monitoring will take place under the direction of our Research Assistant’s 
monthly reports on the number of kits dispensed at each pharmacy. If we are not 
meeting our targets then we will need to make changes in order to ensure the most 
efficacious implementation of this program in these communities. This will be a process 
of continuous quality improvement to ensure the fidelity of program, and will go hand-in-
hand with other measures of implementation evaluation. 
 Beginning in June 2016, a Community Advisory Group (CAG) will begin meeting 
with community leaders from each of our target counties. Meetings will take place in 
Hazard, in Perry County, as the county most central to the area of outreach. During the 
formative phase, meetings will take place once monthly at the Community Center in 
Hazard. Beginning in 2017, meetings will be quarterly at the Hazard Community Center. 
We anticipate interest from the communities will grow upon seeing progress from the 
program, and because this is an area of high poverty and rurality, we will rotate 
meetings among the county seats annually until the program’s conclusion. We also 
hope to bring on additional community members as time progresses and the program’s 
impact is felt by the community. 
 Due to the tightknit nature of Appalachian communities, an advisory committee 
must be formed with individuals who represent and can articulate the values, customs, 
social norms and experiences of the community. We know that in many instances 
perceived “outsider” status of researchers or health educators can be a barrier to 
receiving care in small, rural Appalachian communities.26 In overcoming this burden, our 
current CAG consists of the director of the Bell County Health Department, the pastor of 
Harlan Baptist Church, a physician practicing at Kentucky Rivers Medical Center in 
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Jackson, the founder of Hazard Hates Heroin, the Floyd County Judge-Executive, and 
the pharmacy managers charged with initiating implementation of the program. We also 
desire a combination of those with medical and public health knowledge and those 
without, including health practitioners other than pharmacists. 
 This is reflective of Strategies Guided by Best Practice for Community 
Mobilization. Strategy three is to establish a diverse organization with community 
leaders and residents. It goes on to say to challenge the organization to avoid 
partnering with the groups that seem automatic and focus on more unique approaches. 
These people who have significant influence within the community will be critical for 
getting our community mobilized, which is part of what geared our decision toward our 
five main CAG members.27 
Our Health Department member from Bell County will provide much needed 
perspective from a public health standpoint. She will also know about past interventions 
in these communities and what successes they had or did not have. The pastor from 
Harlan County has been with the families of the victims of this epidemic, held mothers 
as they cried over dead children and spouses as they said they didn’t want to be lied to 
anymore. The pastor is a confidant for many of these people and will have as accurate 
a barometer on the situation as anyone in the community.  The physician from Breathitt 
County will be crucial as a voice for community physicians to help make sure we are 
respecting clinical boundaries and assure other regional practitioners that this is 
addressing a need they are too overburdened to meet. The community leader who 
founded Hazard Hates Heroin lost his daughter to the epidemic and has been lobbying 
in Frankfort for legislative change in addition to holding town forums and bringing in 
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experts. Along with the pastor, he brings in the much needed voice for the people whom 
this situation is directly affecting. Because of his ties with legislators and with community 
residents, he will bring an outside perspective and will be able to add our program to the 
list of things he is promoting in the community to make a change. The Judge-Executive 
from Floyd County brings political leadership on the community level to the CAG, and a 
different perspective to the group aside from medical or personal—she sees daily how 
this is affecting her constituents from the cases brought to the courthouse and the near 
daily calls for EMS to houses where overdose is suspected.  
There are several pharmacies within these communities in addition to the five we are 
initially piloting our intervention. We chose these five pharmacies because they are 
independent, family-owned pharmacies and their pharmacists will not be bound by the 
decisions of their corporate offices regarding what their pharmacists can or can’t do. 
These local pharmacies are the best, in our estimation, to provide access to this OEND 
program. We have the necessary resources in these counties and in these pharmacies 
in order to begin and maintain this program with efficacy.  
After funding has ended for this program, we hope to have curbed overdose rates by 
45%, at a level similar to that of the Massachusetts OEND program over the course of 
three years with a similar level of implementation. It is our hope that due to the hard 
work being put in by our pharmacy staffs on the ground that the program will continue in 
a similar capacity even after CKHPASA is no longer using grant funding to do it. 
Because CKHPASA has members within the community that can speak to the 
education component, community wide education can continue on a volunteer basis in 
the absence of funding.  
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Regarding medication costs, we will continue to supply Evzio®, with manufacturer 
coupons on hand for prescription price assistance—however, these coupons will not 
work with government funded insurance programs like Medicare and Medicaid. During 
the course of the project we will also be working with our grassroots organization 
partners to lobby the Kentucky General Assembly and state Medicaid Managed Care 
Organizations (MCOs) to pay for one Evzio® auto-injector annually per Medicaid patient 
at no cost to the patient. This will not only impact the counties of our intervention but 
Kentucky citizens statewide who would not otherwise have access to afford to keep 
Evzio® on hand. It is our hope that by working on addressing cost issues in the 
beginning of the project, cost will not significantly impact sustainability of the project. 
Should these goals not be attained by the end of the grant period, a transition to a nasal 
actuator will happen in these stores that will more likely be covered by all plans and 
counseling on that route of administration will be a component of patient education. 
C. PERFORMANCE MEASURES AND EVALUTION 
 The pharmacists and staff pharmacists at our stores will monitor the program for 
continuous quality improvement. Although naloxone is not a controlled substance, 
because of its unique position as a drug that can be prescribed by a pharmacist in a 
CCA with a physician, all dispensed prescriptions will be kept on the record as an 
addendum to the controlled substances log. The controlled substances log serves as a 
perpetual inventory that is maintained throughout the day by the pharmacist, and not 
only records quantities dispensed and received, but also the prescription numbers 
assigned each time they are dispensed. This will be the quickest way to track the 
naloxone dispensing record. Additional space will be included in the dispensing record 
OEND	BY	BOARD-CERTIFIED	PHARMACISTS	IN	FIVE	EASTERN	KY	COUNTIES																																																		23	
	
for the patient to sign saying that they have received counseling on knowing the signs of 
opioid overdose and how to administer naloxone using the Evzio® autoinjector. 
Implementation can be evaluated by looking at the acceptance of pharmacists 
and pharmacy staff in the program. If our pharmacists and their staff are enthusiastically 
supportive of the program, they will be huge advocates in their community for sharing 
information about the program with community members. In small towns, pharmacies 
and their staffs are central figures in the healthcare system and as such, carry 
trustworthiness and clout that outsiders may not. Buy-in from the team will help ensure 
a successful implementation. Moreover, we hope that it will also secure the eventual 
spread of the program to other area pharmacies. To measure this, a ten-question 
survey has been developed to measure the pharmacy staff’s perceptions of the 
program, how it is being implemented, and its effectiveness. 
Our pharmacy teams are our seven-days-per-week, on-the-ground staff for this 
project and as such, their feedback is critical on how implementation of the project is 
proceeding. If any portion of implementation needed to be changed, it is they who will 
be aware of the need sooner than the Project Director, who will only be in each county 
twice monthly. As such, this survey will be administered to the pharmacy staff to gauge 
their baseline perceptions beginning June 1, 2016 and then re-administered every six 
months until the completion of the project on May 31, 2019. Data will be analyzed 
across all five sites but also aggregated by pharmacy to see how perceptions change at 
each pharmacy for the duration of the project. Should any changes need to be made, 
that will fall to the Project Director and the pharmacy manager at the site(s) in question 
will collaborate.  
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Process related outcomes can be evaluated by looking at acceptance of the 
programs within the communities they serve. One of the major concerns with OEND 
programs is that they encourage those who are using drugs to keep using them by 
providing them a “safety net”.28 This will no doubt be a concern in this community. 
Reading articles in their local newspapers, including editorials, has shown that many 
community members are not accepting of programs that replace illicit use (like 
Methadone or Suboxone® clinics) and are not open-minded to other harm reduction 
measures like needle exchange programs. We will have to focus carefully on changing 
hearts and minds in this area. Measuring attendance at training sessions on the Evzio® 
auto-injectors at the local library and hopefully seeing growth will help. Engaging 
opponents to these harm reduction measures and asking for their feedback will be 
crucial. It is our hope that showing our data and explaining our information about 
rehabilitation and other helpful tools given with each kit will convince some of these 
opponents to join our cause.  
We know that we must focus on explaining the benefits of harm reduction to 
these communities and how addiction is a non-linear process. At any given point, an 
addict will be moving through the phases of the Transtheoretical Model of Change. One 
relapse will send them back to the beginning again. Addiction is a disease where 
relapse is practically inevitable. NIDA says that 40 to 60% of drug addicts will relapse at 
some point during their recovery and start again. They compare this to the way that 
hypertension or type 2 diabetes worsens with non-adherence to medication therapy and 
finds these rates of “relapse” similar.29 It is important that we stress the importance of 
meeting the addict where they are along their journey and saving a life for today so that 
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they might have that hope for tomorrow. Anecdotes from addicts in recovery about 
hitting their “rock bottom” that made them decide to move beyond those contemplative 
phases of the Transtheoretical Model of Change publish in local media might be one 
way to reach the population with real stories—particularly if “rock bottom” was realizing 
how close their actions brought them to death after surviving an overdose episode. 
To see if those activities make a difference in the area, a fifteen question survey 
about community perception of addiction and overdose reversal will be administered to 
community members every six months, beginning June 1, 2016, until the completion of 
the program. Each administration of the survey will target 25,000 people (5,000 in each 
county) with an estimated return of around 500 surveys per county or 2,500 total. For 
the purposes of sustainability, we want to look at whether or not the community believes 
in the power of this program—if the community doesn’t like the program, it will be 
unlikely to be successful, both for the three-year duration of our grant and for the future. 
If significant gains are made in community acceptance over the course of the project, 
the positive trend from such data could potentially influence neighboring communities to 
adopt a similar model. 
Additionally, we want to holistically evaluate the experience through interviews 
with patients who come into the pharmacy to obtain refill kits after having successfully 
used naloxone to save the life of a loved one. We want to know what the circumstances 
were, the overdose signs they noticed, their comfort and confidence in using the Evzio® 
auto-injector in the situation, and the outcome of the situation. Additionally, we will ask if 
the loved one or the patient has been able to start navigating the Transtheoretical Model 
of Change and by considering using the access to recovery or other provided resources 
OEND	BY	BOARD-CERTIFIED	PHARMACISTS	IN	FIVE	EASTERN	KY	COUNTIES																																																		26	
	
in our naloxone kits after their overdose experience. If there were any negative 
experiences during the overdose reversal situation, including with use of Evzio®, with 
EMS or law enforcement, or at the hospital, we hope to document that as well as 
something to keep in mind for continuously improving the program to make it a better 
experience for the caregivers tasked with administering naloxone in high pressure 
overdose situations. This qualitative analysis will be crucial to understanding the impact 
of this program on individuals within the community. 
In the case of outcome evaluation, we will analyze data from three sources: our 
naloxone dispensing logs, EMS logs, and hospital admission records. Unfortunately, 
many of our intended outcomes will not show up in any studies or analyses because 
unlike the relative ease of access to mortality data regarding death from overdose, data 
from lives saved from overdose will prove more challenging to collect consistently. 
Therefore, this data collection must be approached from multiple angles in order to 
determine if the program is effectively achieving its outcome goals. 
 By keeping a perpetual inventory of naloxone kits dispensed by the program, at 
any given time the pharmacists on staff or the Program Director could look at that 
record and see how many kits have been dispensed to date. This could then be 
compared to our annual goal of 1,350 kits to determine if we are moving toward our 
target goal of kits dispensed within the community. If we are meeting or exceeding our 
goal for number of kits dispensed, we will be able to show that all of our community 
outreach (including but not limited to advertisements, educational forums, school 
programs, etc.) was an effective use of our funding. 
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To analyze the decrease in overdose related death component, we will 
synthesize data from multiple sources. Because patients will most likely need to utilize 
EMS to get to an emergency room—as one dose of naloxone will only give them an 
extra hour or so before overdose symptoms begin again (depending on the half-life of 
the opioid ingested)—there will be documentation of overdose treatment at area 
hospitals. We will obtain agreements with hospitals for access to electronic medical 
record data showing successful overdose reversals or post-reversal treatment at the 
hospital. In agreement with these hospitals, the patients coming in for overdose will be 
asked if they used naloxone prior to EMS arrival and if so, where they obtained it from. 
Patients will be required to sign a release of information to the program in order for us to 
access their medical records and use them in our research. This component will be 
discussed when the kit is first dispensed, with the reminder that all information obtained 
by this program will be used to help demonstrate the effectiveness of it and all personal 
identifiers will be removed. 
We can also collect data from EMS dispatch regarding calls to homes for 
suspected overdose and whether, prior to EMS arrival, naloxone reversal had been 
attempted. This would catch cases that utilized hospitals outside of our five county 
scope of our intervention or if, after EMS arrived and monitored the patient, they 
determined no further treatment was necessary. Again, EMS personnel would carry 
those release of information forms with them on their calls and have the patient sign 
them if they belong to our program. 
Within the pharmacy itself, another way to determine if a kit was used to 
successfully reverse an overdose would be to track repeat visits to the pharmacy by 
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patients to obtain a naloxone kit refills. If the kit was used, the assumption can be made 
that overdose reversal was attempted. Each refill initiation will trigger the special 
counseling mentioned above in process evaluation, and the outcome of that overdose 
can be documented for outcome evaluation as well.  
The trouble with these outcome evaluation measures is that there will be 
potential inaccuracies with missing data or in some instances, duplicate data regarding 
use of the kits dispensed. However, these methods will be as effective as possible and 
give a generalized look at the success of the program.  
One final method of outcome evaluation that we will complete annually is to 
analyze the trends in overdose deaths in the five counties. Again, our target is to 
decrease those deaths by 46% over the course of three years. Steady downward trends 
over the duration of the program in overdose mortality in the five intervention counties 
will be an indicator that an OEND program that increases access to and education 
about naloxone in these communities is an effective way to combat this crisis.  
 Five measures that should be added to annual state Behavioral Risk Factor 
Surveillance System (BRFSS) surveys regarding this topic that may show the 
effectiveness of the program pre- and post-implementation are as follows: 
1) Do you know someone who abuses opiates of any kind (heroin, oxycodone, 
Lortab®, Percocet®, Opana®)? 
2) Have you ever known someone to be hospitalized or taken by ambulance after 
suffering an overdose from using a drug not prescribed to them? 
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3) Have you ever known someone who has died from an overdose on one of those 
substances? 
4) Have you ever known anyone who keeps a Naloxone kit at home that they got from 
a pharmacy to use for themselves or a loved one to use to reverse a drug overdose? 
5) Have you ever known someone who used one of those kits to reverse their overdose 
and prevent their death? 
Ideally, even if the frequencies for question 1 stay constant, questions 2 and 3 
may show a decrease, and questions 4 and 5 may show an increase if our program is 
effective and reaching our target population. 
Over the course of the project we hope that the data obtained from these surveys 
and interviews will help us identify key successes, challenges, and lessons learned with 
implementation of the program so that other communities can better adapt it. As data 
comes in every six months in most instances, we can look to see if we are making our 
goals, and if not, we can continue continuous quality improvement measures under the 
direction of the Program Director, Research Assistant, and the staff of each pharmacy. 
 
D. CAPACITY OF APPLICANT ORGANIZATION 
 The Coalition of Kentucky Health Professionals Against Substance Abuse 
(CKHPASA) encompasses members of varying health professions working in an 
interdisciplinary manner to tackle the issue of substance abuse in Kentucky. Members 
of the organization have prior experience educating college students about the risks of 
substance use through a partnership with the Association of Independent Kentucky 
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Colleges and Universities. This grant allowed physicians, pharmacists, nurses, social 
workers, and public health professionals to educate students at colleges averaging 
1,000 students in enrollment using evidence-based programs that target initiation of 
substance abuse in college—particularly stimulants used as study aids. 
 This program has been distilled to work in high school populations in counties 
where substance abuse initiation beginning during the teen years is prevalent. That 
program was adapted and merged with Media and Me, which challenges high school 
students to become more aware of both direct and subtle messaging about alcohol and 
drug use across multiple media platforms. Therefore, we have experience in adapting 
and tailoring evidence-based programming.  
This hybrid program was presented in counties where teens were significantly at 
risk for substance abuse initiation. It has been previously taken to Harlan County where 
presentations were given at Harlan County High School and Harlan High School. 
Whenever possible in these high school programs, coalition members from the area 
serve as facilitators for discussion—in fact, there are coalition members in all 120 
Kentucky counties, so our reach across the state is broad and impactful—we aren’t 
necessarily “outsiders” coming in to intervene in a community, because a trusted and 
respected member of the community is there advocating for us. 
This program has continued in Harlan County through volunteers who live in the 
area and are CKHPASA members. Volunteers and educators in the high schools 
wanted to make sure that this program reached each subsequent incoming freshman 
class because of it’s impact on increasing awareness of subtle media messaging 
involving drugs—particularly the message that “everyone is doing it.” There has been a 
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decrease in substance abuse initiation, particularly with prescription opioids in this 
population in Harlan County. In fact, of the twelve grant-funded programs we have been 
a part of since 2010, all twelve continued to be implemented in some form or fashion in 
their community. We believe this is in no small way due to our members varied 
backgrounds and their ability to secure funding and resources from outside 
organizations after grant-funding has ended and to influence the communities they live 
in that these programs are worth being continued. 
 CKHPASA has been able to provide training and technical assistance to support 
other organizations implementing evidence-based programs—particularly in training lay 
health workers, as we have done in Fayette County in targeting alcohol abuse in 
minority populations. Our training allowed persons from that minority to group to do 
significant outreach that our organization could not have done alone. 
Performance measure data was collected via surveys administered by the lay 
health workers in live interviews. Every four months this data was analyzed to see if 
there were changes in the rates of alcohol consumption in each minority population. In 
our commitment to continuous quality improvement, this data was used to determine if 
we needed to make program improvement, and if so, where that needed to take place. 
If trends were suggesting a decrease in the African-American and Asian-American 
populations but an increase among the Hispanic population, we would go to the lay 
health workers we had in the Hispanic community to determine if there was something 
we could do to improve outreach. After a few tweaks to the education component mostly 
involving translation, we saw the Hispanic population begin to decrease their alcohol 
consumption as well.  
OEND	BY	BOARD-CERTIFIED	PHARMACISTS	IN	FIVE	EASTERN	KY	COUNTIES																																																		32	
	
 The mission of the CKHPASA is to use health professionals to reach 
Kentuckians with information on the dangers associated with substance abuse, and also 
to provide resources with the goal of sobriety in populations where drug use is 
prevalent. Health professionals are highly educated and trained in these issues and by 
bringing in members from different practice types, CKHPASA can offer a full range of 
education and resources for their target populations. CKHPASA envisions a Kentucky 
that no longer leads the nation in drug overdose death rates (CDC), but in successful 
recovery. 
 In OD-NAP EKY, we are targeting both aims of the vision of CKHPASA and the 
mission of CKHPASA. By distributing literature with the naloxone kits that explain signs 
and symptoms of overdose, dangers of unreversed overdose, and the way naloxone 
works to stop overdose, CKHPASA is educating addicts and their loved ones about the 
overdose process and helping loved ones make good decisions regarding overdose 
(e.g., calling an ambulance immediately after administration of naloxone because the 
addict will likely need at least one more dose). By holding seminars about opiate abuse 
and overdose at the library, and including resources for recovery in the kits, CKHPASA 
can help reduce the state’s number of substance abusers. The overall goal of the 
program is to decrease the number of overdose deaths in these communities gripped 
with devastatingly large losses. 
 Our board leadership is committed to the goal of reducing drug overdose in these 
five counties. Dr. Maureen Johnson, who is the Project Director, is a sitting board 
member and wanted to take on this role because of her passion for removing these 
access barriers and providing harm reduction in communities with demonstrated need. 
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Dr. Johnson will be leaving her position as a community pharmacist in order to take on 
this role. In addition to quarterly meetings at our headquarters in Frankfort, we also hold 
regional monthly meetings at rotating sites. Our board members wanted this to be a key 
component of our organization’s structure so that leadership could hear from all 
members of the organization, not just the board or those who could attend the quarterly 
meeting. Our members listen to their communities and are engaged in helping combat 
the substance abuse crises that hit closest to home for them.  
 Because we are of the community we always want to bring community ideas to 
the table and acquire “champions” from the community to help promote the program 
and mobilize resources—this is especially key for sustainability components, and the 
way we have been able to rally our communities around these interventions has meant 
improved outcomes related to substance abuse throughout the state of Kentucky. 
 Many organizations experience decreases in membership or high turnover rates 
as time goes on. We have found that very few of our health professionals get the 
opportunity to practice in multi-disciplinary settings and that when our members come 
together for meetings and trainings, they enjoy hearing how the other professions 
approach problems and look for solutions. They think that approaching the issue of 
substance abuse from multiple perspectives will provide more holistic and ultimately 
helpful solutions. After the planning is over and the implementation begins, they enjoy 
this opportunity to be able to be ambassadors for their communities to help curb 
substance abuse and then, if the intervention is proven successful, look forward to 
sharing their success with members in other regions and following up on the success of 
those disseminations.  
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Finally, CKHPASA does not and shall not discriminate on the basis of race, color, 
religion (creed), gender, gender expression, age, national origin (ancestry), disability, 
marital status, sexual orientation, or military status, in any of its activities or operations. 
These activities include, but are not limited to, hiring and firing of staff, selection of 
volunteers and vendors, and provision of services. We are committed to providing an 
inclusive and welcoming environment for all members of our staff, clients, volunteers, 
subcontractors, vendors, and clients. If the membership of CKHPASA discovers that 
any member on an outreach project is in violation of this policy, that member shall be 
permanently banned from the organization and removed from the project. 
E. PARTNERSHIPS AND COLLABORATION 
 CKHPASA will partner with several organizations throughout the target 
communities. Because of their existing grassroots work within these communities, we 
will partner with Hazard Hates Heroin, Jackson Hates Heroin, and Eastern Kentuckians 
Against Prescription Drug Abuse to help disseminate information about the availability 
of naloxone and recovery resources in our pharmacies. These organizations were all 
founded by family members of persons lost to heroin or prescription opiate overdose, 
and their community forums and local activism target both addicts to get them into 
treatment but also loved ones of addicts to help them both cope with the emotional toll 
of caring for an addict. Many of the founding members are also vocal in campaigning in 
Frankfort for legislative change—the founder of Harlan Hates Heroin was an 
instrumental voice in lobbying area members of the state General Assembly for some of 
the provisions of SB 192. We will collaborate with these organizations to hold sessions 
for addicts and their loved ones to help them become comfortable and confident in 
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using the Evzio® auto-injectors dispensed by our pharmacies through repeated 
practice. 
 For the purposes of these training exercises, we have partnered with Kaléo 
Pharmaceuticals, the manufacturer of Evzio®. Kaléo, based in Richmond, Virginia, has 
a philosophy regarding patient-centered care that is unique among pharmaceutical 
companies. They specialize in medications to assist patients in life saving emergencies 
and delivery systems for those medications that are patient and caregiver friendly. They 
have generously donated 50 training devices that may be used 1,000 times each that 
we can utilize at training sessions. 
We will also partner with the local public library in each of the five counties to 
host forums and information nights. The library is an excellent choice for these events 
because they will always be free and open to the public and in a “neutral” space. These 
monthly forums will also address community concerns regarding access to naloxone 
and will prominently feature trusted community members invested in the program in 
order to increase acceptance among the communities at large. We know from our prior 
experience working in this area with high school students in Harlan County that putting 
people who are familiar with the area and its particular challenges and can offer 
relatable, specific anecdotes about the region yielded far more successful interactions 
than those that featured people perceived by the community as “outsiders.” 
Partnerships will be continued with the high schools in Harlan County but will 
also disseminate to the high schools in the other target counties in the first year, with 
expansion into middle schools by year two. Annual presentations will be given to the 
students at these schools similarly to past successful programs put on by CKHPASA 
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surrounding the prescription drug epidemic with tailoring to incorporate and feature 
heroin. In response to CDC data that exists showing that 5.2% of Kentucky high 
schoolers have used heroin, the school boards in each county also recognize the need 
for this program. Education will involve the dangers of abuse (including overdose) from 
the physical to the financial and social. A significant piece of this program will include 
information on the availability of take-home naloxone kits in their communities. In 
addition to those 5.2% of students who are potentially abusing heroin, many more may 
know classmates, family, or friends that we will have given them the tools to advocate 
the importance of having naloxone on hand to those loved ones.  
Additional partnerships have been secured with the Chambers of Commerce in 
each county. Member businesses will be a key partner in helping to advertise the 
program through the placement of flyers and other information regarding the program 
and the education opportunities at the libraries. Many chamber members have also 
expressed interest in the program because they have dealt with the consequences of 
accidental overdose on the premises of their businesses and want to have kits on hand 
that they can be trained to use by our program’s pharmacists. Buy-in from these local 
community business leaders is critical to increased acceptance in the community.  
 Perhaps most obviously, we will need to partner our pharmacies with the medical 
communities in each county. Ideally, we will partner with one physician in each county in 
order to establish the CCAs necessary to dispense the naloxone kits in our pharmacies. 
For the purposes of data collection regarding utilization of the kits dispensed by the 
pharmacy, we will partner with local hospitals. These partners at the hospital will be 
crucial in helping to determine if patients being admitted for overdose reversal are 
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patients who had utilized naloxone at home before the ambulance was called, and if 
that is the case, where they obtained the naloxone from. 
F. PROJECT MANAGEMENT 
CKHPASA has the personnel to successfully implement and evaluate this project 
over the three year grant period. In recognizing that the addiction and substance abuse 
that leads to accidental overdose is a multi-faceted problem, CKHPASA has chosen 
from its membership a project staff of varied skills and training. Our personnel are 
trained in public health, pharmacy, social work, and osteopathic medicine and thus bring 
a variety of perspectives to the issue of harm reduction through OEND.  
Dr. Joanne Jefferson, Principal Investigator:  Dr. Jefferson has over 24 years of 
university teaching experience during which she has taught a total of 41 different 
courses. Currently a professor at Eastern Kentucky University in the Public Health and 
Health Promotion and Administration departments, she teaches coursework on Drugs, 
The Individual, and Society and Death & Grief.  Dr. Jefferson received her 
undergraduate and graduate degrees from the University of Wisconsin and her PhD 
from Purdue University. Dr. Jefferson also currently serves as a board member for the 
Kentucky Agency for Substance Abuse Policy.   
Dr. Jefferson, as our Principal Investigator, will be managing data collection for 
packaging to our data analyst. Once this process is complete, she will be responsible 
for writing about the outcomes of the project for publication in the literature. Her 
background in public health and particularly in the role of how drug use affects not only 
the individual but their surrounding community and society as a whole will be integral for 
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her work toward publication. Additionally, as the program is concluding, Dr. Jefferson 
will speak (alongside Dr. Johnson) to the Kentucky General Assembly in their 2019 
session in order to advocate for similar programs like this throughout the state and for 
Medicaid coverage of Evzio®. 
Dr. Maureen Johnson, Project Director: Dr. Johnson is a recent alumnus of the 
University of Kentucky College of Pharmacy and the University of Kentucky College of 
Public Health, where she simultaneously earned her PharmD and MPH through the 
Department of Health Behavior. Her practicum site in preparation for graduation with the 
MPH was at the Polk Dalton Clinic working with Dr. Mark Cohen in the Subutex® clinic 
for pregnant women with comorbid opiate addiction. Additionally, she has partnered with 
Northern Kentucky Hates Heroin to produce media describing the devastation of the 
heroin epidemic in Kentucky including music videos that have reached thousands 
online.  
Dr. Johnson, serving as our Project Director, will be our main leadership on the 
ground in the intervention counties. She will be responsible for visiting each site twice 
monthly starting January 1, 2017. While in the community, she will also lead most of the 
education sessions at the public libraries and public schools, with assistance from Dr. 
Schunard. She will also be responsible for the dissemination of sensitivity training at the 
intervention pharmacies. Additionally, after analysis is complete on semi-annual surveys 
of pharmacy staff and the community, Dr. Johnson will turn to that data to see where 
attitudes and perceptions are either not improving or worsening. If either is the case, 
she will be responsible for leading plans to make changes to the program or its 
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dissemination to better improve results on performance evaluation measures and thus 
the success of the program as a whole. 
Dr. Mimi Marquez, Project Co-Coordinator: Dr. Marquez holds several positions in 
the College of Pharmacy at the University of Kentucky, including Director of the Center 
for the Advancement of Pharmacy Practice (CAPP); Clinical Associate Professor in the 
Pharmacy Practice and Science Department, and affiliated faculty member in the 
Institute for Pharmaceutical Outcomes and Policy (IPOP). She received a bachelor of 
pharmacy degree and a Ph.D. degree from the University of Kentucky, and completed 
postdoctoral fellowships at the University of Vermont College of Medicine and the UK 
College of Medicine. Dr. Marquez currently teaches a course through the University of 
Kentucky College of Pharmacy to train licensed Kentucky pharmacists in naloxone 
dispensation to earn their state mandated certificates.  
Dr. Marquez will primarily be responsible for education and training with our 
pharmacy staffs. She will teach the course for pharmacists to become naloxone certified 
through her position at the University of Kentucky College of Pharmacy. She will also 
assist Dr. Johnson in the sensitivity training of the staff at each pharmacy. She will 
collaborate with Dr. Jefferson through her role in the Institute for Pharmaceutical 
Outcomes and Policy in helping shape the post-project publication. 
Dr. Roger Davis, Data Analyst: Dr. Davis joined the department of Bioinformatics 
and Biostatistics at the University of Louisville in 2003 as a statistician with the 
Statistical Consulting Center. He has a PhD in Applied and Industrial Mathematics, an 
MSPH in Biostatistics and Decision Science, and a MA in Mathematics all from the 
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University of Louisville. He has collaborated with 100+ investigators within and outside 
the University of Louisville. A member of the teaching faculty at the university since 
2011, his primary research interest is in survival analysis and generalization of survival 
data.  
Dr. Davis is charged throughout the duration of this project with synthesizing data 
obtained from our various forms of evaluation. He will do analysis of the results of two 
different surveys twice yearly and will also analyze data on naloxone utilization and 
overdose death figures annually. Additionally, he will assist Dr. Jefferson by lending his 
expertise to the statistical analysis portion of the publication.  
Dr. Angel Dumott Schunard, Field Educator: Dr. Schunard is an Associate 
Professor of Social Work within the Sociology, Social Work, and Criminology 
department at Morehead State University. She earned her MSW and PhD at the 
University of Kentucky. Dr. Schnuard’s areas of interest are: substance 
use/abuse, criminal justice system involvement, and treatment-seeking behaviors. She 
has published in peer-reviewed journals on topics including: substance use/abuse, 
intimate partner violence, and pregnancy. She is currently the PI for multiple evaluation 
projects examining outcomes associated with participation in community-based 
substance abuse treatment services (e.g., Drug Court) funded by the Substance Abuse 
and Mental Health Services Administration Center for Substance Abuse Treatment.   
Dr. Schunard’s experience in social work and in substance abuse treatment will 
make her an asset for developing our brochure of resources to be inserted in each 
naloxone kit. Additionally, Dr. Schunard will assist Dr. Johnson with the development of 
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the educational components of our program in local high schools and at public libraries 
and any materials disseminated in those programs.  
Benjamin Coffin III, Research Assistant: Mr. Coffin is a Doctor of Osteopathy 
student at the Kentucky College of Osteopathy in Pikeville. Mr. Coffin has a particular 
interest in addiction medicine and has been involved in research projects on campus 
studying the variance in dosage leading to overdose events using morphine in rats.  
Mr. Coffin’s proximity to the area compared to the rest of the staff will make him 
essential for quick response to emergent situations. His main role will be in compiling 
data on prescription naloxone dispensing at each of the local pharmacies by looking at 
monthly dispensing snapshots to ensure that the program is functioning at the desired 
level of operation. By making those analyses monthly, Mr. Coffin will be able to see 
areas for improvement much more quickly and any necessary changes regarding 
recruitment or advertising could be implemented at sites showing need for 
improvement. 
The project management team will meet quarterly at CKPHASA headquarters in 
Frankfort, Kentucky. In those times where the team is not meeting in person, group e-
mails and text messages will be utilized so that any important feedback, particularly if it 
is determined that outcome or implementation goals are not being met, can be 
addressed before the next quarterly meeting.  
Annual professional development meetings will be held in January for the team at 
CKPHASA headquarters. Additionally, participation of the project management teams in 
their regional monthly CKPHASA meetings which will continue to provide training on 
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achieving the missions of the organization in educating their local communities on 
substance abuse related policies and initiatives. By remaining active in CKPHASA, our 
project management team will be exposed to the latest evidence-based education 
approaches throughout the health disciplines and will be kept abreast of changing state 
policy and legislation that may impact the various programs and projects being 
implemented by our members across the state of Kentucky. This involvement in a fun, 
positive, enriching environment will help us ensure little to no staff turnover and 
increased staff engagement. 
By utilizing CKPHASA resources, especially members of the organization as 
members of our project management team and community partners, we will be able to 
sustain this program in the communities targeted in this intervention. The training and 
feedback those members provide to the organization will be essential for CKPHASA 
members residing in all 120 Kentucky counties to disseminate the successful program 
across the state of Kentucky. 
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Appendix A 
Logic Model 
 
Inputs  Outputs  Outcomes & Impact 
Resources    Activities Participation  Short-Term  Intermediate Long-Term 
        
Pharmacy Staff 
 
- Pharmacy 
Managers 
- Staff Pharmacists 
- Intern Pharmacists 
- Technicians 
- Clerks 
 
Partners 
- CKHPASA 
- Hazard Hates 
Heroin   
- Kaléo 
Pharmaceuticals    
- Public Library 
System  
- County High 
Schools  
- Chambers of 
Commerce  
- Physicians in 
CCAs  
- Local Hospitals 
 
Naloxone Kits 
Patients/Caregivers 
Community 
Advisory Group 
Project Staff 
Funders 
 - Necessary training 
completed to obtain 
naloxone certification 
 
- Sensitivity training  
 
- Building of naloxone 
kits that contain one dose 
of naloxone, alcohol 
swabs, CPR mask, 
connections to opioid 
replacement therapy 
clinics and rehabilitation 
facilities 
 
- Training of patients and 
loved ones on signs of 
opioid overdose, use of 
Evzio®, when to involve 
EMS, and Good 
Samaritan laws 
  
- Maintenance of Evzio® 
dispensing logs, 
monitoring hospital 
admissions and EMS 
calls                
  
- Monthly meetings at 
local libraries to train 
citizens and link them to 
the program         
  
- Education at area high 
schools 
 
- Recruitment through 
advertisement at 
businesses affiliated with 
Chamber of Commerce 
- Pharmacy staff 
at one pharmacy 
in each of the five 
counties 
 
- One physician in 
each county in a 
CCA 
  
- CAG members 
  
- Members of 
CKHPASA 
  
- Community 
partners 
  
- Hospital records 
department 
  
- Citizens of 
community 
attending 
educational 
events 
 
- Students at area 
high schools  
  
- Addicts and/or 
their loved ones 
 
- Local business 
leaders in 
Chamber of 
Commerce 
 
- Representatives 
of Kaléo Pharma 
 - Increased access to 
Overdose Education 
and Naloxone 
Distribution (OEND) via 
pharmacists in CCAs 
with local physicians 
 
 
 
- Increased awareness 
in the five intervention 
counties of the ability of 
naloxone to reverse 
opioid overdose while 
waiting on EMS to 
arrive 
 
 
 
 
- Increased education 
on opioid addiction, 
recovery, and the 
benefits of having 
naloxone in the home 
 
 
 
 
- Increased number of 
community members of 
obtaining a naloxone 
kit, being trained on its 
administration, and 
recognizing the signs of 
overdose annually 
 
 
 
- Increasing the reach of 
the program by 1% 
annually 
 
 
 
- Decrease in overdose 
mortality in the five 
intervention counties by 
45% by year three of 
the intervention 
 
 
 
- Increased community 
interest in OEND 
through 20% increase in 
attendance at education 
nights by year three of 
the intervention 
 
 
 
- Increased community 
acceptance of OEND 
(as evidenced by 
increase positive 
responses to questions 
4 and 5 on our 
evaluation) 
 
 
 
 
- Continued sustainability 
of OEND after the end of 
the program utilizing the 
pharmacists already 
trained within these five 
pharmacies and broad 
dissemination in other 
counties throughout KY 
 
 
 
- Utilization of Evzio® 
coupon cards and prior 
authorizations to maintain 
low or no cost access to 
the auto-injectors 
 
 
 
- Decrease in overdose 
mortality in the five 
intervention counties by 
70% within five years 
 
 
 
- Increased utilization of 
recovery facilities and 
other treatment, 
decreasing the number of 
opioid addicts in the 
community  
 
 
- Continued community, 
high school, and 
employer education on 
drug abuse prevention 
and control by members 
of CKHPASA 
  
  
Appendix B 
Work Plans 
Work Plan #1 
June 1, 2016 – December 31, 2016 
 
 
Grantee Name    CKHPASA                                                                                        Funds Requested    $750,000 
 
Goal I: Pharmacy staff at each of the five pilot pharmacies to initiate naloxone kit dispensing on January 1, 2017. 
 
 
Objective I: All pharmacists at each of the five pilot pharmacies to obtain naloxone certification and all staff members at the pharmacy to complete 
the developed sensitivity training program within the first six months of the grant period and adapt dispensing model to allow accurate record 
keeping of naloxone distribution.  
 
 
Rationale for Objective I: State law mandates that all pharmacists who want to dispense naloxone secondary to a CCA with a physician must 
receiving training and certification through the Kentucky Board of Pharmacy. Due to the rurality of the pharmacies, sensitivity training must be 
completed to ensure HIPAA is being followed and addicts and their loved ones are not being stigmatized for seeking help. 
 
 
Measures of Accomplishment for Objective I: 
 
a. Naloxone certifications distributed by the Kentucky Board of Pharmacy to each staff pharmacist. 
 
b. Each pharmacy staff member completing a post sensitivity training questionnaire. 
 
c. Naloxone dispensing logs created and bound. 
Activities in support of Objective I: 
 
 
a. Training trips to the University of Kentucky 
College of Pharmacy for staff pharmacists to 
obtain certification. 
 
b. Creation of naloxone log by each pharmacy. 
 
c. Sensitivity training events hosted at each of 
the five implementing pharmacies for entire 
staff. 
Person/agency responsible for 
Accomplishing Activities: 
 
a. Mimi Marquez, Project Co-Coordinator 
 
b. Maureen Johnson, Project Director / 
Pharmacy Managers 
 
c. Maureen Johnson, Project Director / Mimi 
Marquez, Project Co-Coordinator 
Activity Timeline: 
 
 
a. By November 1, 2016 to allow for ease of 
scheduling. 
 
b. By December 1, 2016 to allow changes to 
be made to the log if necessary. 
 
c. By December 31, 2016, one session at each 
pharmacy hosted at a time convenient to staff. 
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Work Plans 
Work Plan #2 
January 1, 2017 – May 31, 2019 
 
 
Grantee Name    CKHPASA                                                                                        Funds Requested    $750,000 
 
Goal I: Increase in the number of naloxone kits dispensed to addicts or their loved ones annually. 
 
 
Objective I: Kits dispensed to 1% of the total populations of all five counties annually (1,350) for a total of 3,375 kits dispensed in the thirty months 
of post-planning program implementation, between January 1, 2017 and May 31, 2019. 
 
 
Rationale for Objective I: Because an estimated 30% of the community will know someone actively addicted to opiates but because there will be 
overlap in the known addict, we want to target about 10% of the community for the overdose education component but we expect to only serve 
about 1% of the total population annually with overdose kits. This is because each addict in the community might have several family members but 
only one kit would be needed in that instance. There may also be a stigma component in seeking the kits because of the small town atmosphere 
and worry that other community members would “find out” you or a loved one was on drugs, which may reduce the number of persons actually 
obtaining kits. 
 
Measures of Accomplishment for Objective I: 
 
a. Naloxone distribution across all five counties meets or exceeds the goal of 3,375 kits dispensed by May 31, 2019. 
 
b. Year end total for 2017 meeting or exceeding 1,350 kits. 
 
c. Year end total for 2018 meeting or exceeding 2,700 kits. 
Activities in support of Objective I: 
 
a. In-pharmacy and community advertisement 
(through Chamber of Commerce) of the 
availability of our OEND program. 
 
b. Annual education in each high school of the 
target counties about OEND and addiction.  
 
c. Community education nights and forums to 
teach community members about OEND and 
addiction. 
Person/agency responsible for 
Accomplishing Activities: 
 
a. Maureen Johnson, Project Director / Staff 
Pharmacists / Chamber of Commerce 
Members 
 
b. Maureen Johnson, Project Director / Angel 
Dumott Schunard, Field Educator 
 
c. Maureen Johnson, Project Director / 
CKPHASA / Angel Schunard, Field Educator 
Activity Timeline: 
 
a. Beginning before implementation in late 
December 2016 and lasting until May 2019. 
 
b. Each year in the Spring Semester, 
beginning in Spring 2017 and continuing until 
Spring 2019. 
 
c. Beginning January 1, 2017 once monthly in 
the public library of each county through May 
31, 2019. 
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Work Plan #3 
January 1, 2017 – May 31, 2019 
 
 
Grantee Name    CKHPASA                                                                                        Funds Requested    $750,000 
 
Goal I: Decrease opioid overdose mortality in each intervention county. 
 
Objective I: Overdose deaths in the five intervention counties decreased by 45% before the culmination of the grant period on May 31, 2019, with 
a steadily decreasing number of annual deaths over the course of the project. 
 
Rationale for Objective I: By targeting the population that needs this intervention most and with increasing numbers of kits dispensed annually, 
and because these targets match “high implementer” communities in the Massachusetts OEND program, we expect to see a similar decrease in 
opioid overdose related death in the five intervention counties as the Massachusetts program saw over a similar timeframe. 
 
Measures of Accomplishment for Objective I: 
 
a. Analysis of opioid overdose deaths in the community showing a continued downward trend in the number of overdose deaths. 
 
b. Hospital/EMS records and Evzio® refill records indicating that the number of those surviving overdose is increasing. 
 
c. Increased community awareness of the positive outcomes of OEND by increased positive response on the community evaluation survey with 
the number of positives responses increasing annually. 
Activities in support of Objective I: 
 
 
a. Annual analysis of overdose death mortality 
reported in each of the five counties. 
 
b. Annual analysis of Hospital/EMS records 
and pharmacy refill records compared to 
number of kits dispensed. 
 
c. Annual implementation survey of the 
community at large to assess community 
acceptance of the OEND program. 
 
Person/agency responsible for 
Accomplishing Activities: 
 
a. Roger Davis, Data Analyst 
 
b. Maureen Johnson, Project Director / Roger 
Davis, Data Analyst / Benjamin Coffin III, 
Research Assistant 
 
c. Maureen Johnson, Project Director / Roger 
Davis, Data Analyst / Benjamin Coffin III, 
Research Assistant 
Activity Timeline: 
 
a. Reports due annually, final cumulative 
report and analysis of project duration trends 
due on May 31, 2019. 
 
b. Quarterly totals due beginning March 1, 
2017 with annual analysis synthesizing data 
due in January of each year and final report 
due on May 31, 2019. 
 
c. Surveys performed annually in December 
and data analyzed from those surveys by 
January 31 of the following year. Final program 
duration analysis due on May 31, 2019. 
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Budget Item Year One Year Two Year Three Project Totals 
Salary/Wages $191,000 $202,651 $221,077 $614,728 
Fringe Benefits $66,829 $69,999 $74,627 $211,455 
Naloxone Kits $348,395 $348,395 $348,395 $1,045,185 
Equipment/Supplies $4,000 $2,000 $2,000 $8,000 
Travel $23,664 $33,664 $33,664 $90,992 
Other $55,000 $50,000 $45,000 $150,000 
     
Annual Totals $688,888 $706,709 $724,763 $2,120,360 			
A. Salaries and Wages 		
  Year One Year Two Year Three 
Project Member Position Salary Effort Amount  
Requested 
Salary Effort Amount 
Requested 
Salary Effort Amount 
Requested 
Dr. Joanne Jefferson Principal 
Investigator 
$80,000 20% $16,000 $85,296 20% $17,059 $93,671 20% $18,734 
Dr. Maureen Johnson Project Director $85,000 100% $85,000 $90,627 100% $90,627 $99,526 100% $99,526 
Dr. Mimi Marquez Project Co-
Coordinator 
$100,000 35% $35,000 $106,620 35% $37,317 $117,089 35% $40,981 
Dr. Roger Davis Data Analyst $60,000 20% $12,000 $63,972 20% $12,794 $70,253 20% $14,051 
Dr. Angel Dumott 
Schunard 
Field Educator $70,000 40% $28,000 $74,634 40% $29,854 $81,962 40% $32,785 
Benjamin Coffin III Research Assistant $15,000* 100% $15,000 $15,000* 100% $15,000 $15,000* 100% $15,000 
 
Annual Totals  $191,000  $202,651  $221,077 	
 
Total, Salaries and Wages: $614,728 
 
Principal Investigator, Dr. Joanne Jefferson (20%, 2.4 months, Years 1-3) – Dr. Jefferson has over 24 years of university 
teaching experience during which she has taught a total of 41 different courses. Currently a professor at Eastern Kentucky University in 
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the Public Health and Health Promotion and Administration departments, she teaches coursework on Drugs, The Individual, and 
Society and Death & Grief.  Dr. Jefferson received her undergraduate and graduate degrees from the University of Wisconsin and her 
PhD from Purdue University. Dr. Jefferson also currently serves as a board member for the Kentucky Agency for Substance Abuse 
Policy. 
Dr. Jefferson, as PI, will be devoting 20% effort annually to the project. She will be responsible for all aspects of the project and will 
be managing data collection for packaging to our data analyst. Once this process is complete, she will be responsible for writing about 
the outcomes of the project for publication in the literature. Her background in public health and particularly in the role of how drug use 
affects not only the individual but their surrounding community and society as a whole will be integral for her work toward publication. 
Additionally, as the program is concluding, Dr. Jefferson will speak (alongside Dr. Johnson) to the Kentucky General Assembly in their 
2019 session in order to advocate for similar programs like this throughout the state and for Medicaid coverage of Evzio®. 
Project Director, Dr. Maureen Johnson (100%, 12 months, Years 1-3) – Dr. Johnson is a recent alumnus of the University of 
Kentucky College of Pharmacy and the University of Kentucky College of Public Health, where she simultaneously earned her PharmD 
and MPH through the Department of Health Behavior. Her practicum site in preparation for graduation with the MPH was at the Polk 
Dalton Clinic working with Dr. Mark Cohen in the Subutex® clinic for pregnant women with comorbid opiate addiction. Additionally, she 
has partnered with Northern Kentucky Hates Heroin to produce media describing the devastation of the heroin epidemic in Kentucky 
including music videos that have reached thousands online. 
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Dr. Johnson will be completely grant funded for the duration of the project. She will be our main leadership on the ground in the 
intervention counties. She will be responsible for visiting each site twice monthly starting January 1, 2017. While in the community, she 
will also lead most of the education sessions at the public libraries and public schools, with assistance from Dr. Schunard. She will also 
be responsible for the dissemination of sensitivity training at the intervention pharmacies. Additionally, after analysis is complete on 
semi-annual surveys of pharmacy staff and the community, Dr. Johnson will turn to that data to see where attitudes and perceptions are 
either not improving or worsening. If either is the case, she will be responsible for leading plans to make changes to the program or its 
dissemination to better improve results on performance evaluation measures and thus the success of the program as a whole. 
Project Co-Coordinator, Dr. Mimi Marquez (35%, 4.2 months, Years 1-3) – Dr. Marquez holds several positions in the College of 
Pharmacy at the University of Kentucky, including Director of the Center for the Advancement of Pharmacy Practice (CAPP); Clinical 
Associate Professor in the Pharmacy Practice and Science Department, and affiliated faculty member in the Institute for 
Pharmaceutical Outcomes and Policy (IPOP). She received a bachelor of pharmacy degree and a Ph.D. degree from the University of 
Kentucky, and completed postdoctoral fellowships at the University of Vermont College of Medicine and the UK College of Medicine. 
Dr. Marquez currently teaches a course through the University of Kentucky College of Pharmacy to train licensed Kentucky pharmacists 
in naloxone dispensation to earn their state mandated certificates.  
Dr. Marquez, at 35% effort, will mainly be responsible for education and training with our pharmacy staffs. She will teach the course 
for pharmacists to become naloxone certified through her position at the University of Kentucky College of Pharmacy. She will also 
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assist Dr. Johnson in the sensitivity training of the staff at each pharmacy. She will collaborate with Dr. Jefferson through her role in the 
Institute for Pharmaceutical Outcomes and Policy in helping shape the post-project publication. 
Data Analyst, Dr. Roger Davis (20%, 2.4 months, Years 1-3) – Dr. Davis joined the department of Bioinformatics and Biostatistics 
at the University of Louisville in 2003 as a statistician with the Statistical Consulting Center. He has a PhD in Applied and Industrial 
Mathematics, an MSPH in Biostatistics and Decision Science, and a MA in Mathematics all from the University of Louisville. He has 
collaborated with 100+ investigators within and outside the University of Louisville. A member of the teaching faculty at the university 
since 2011, his primary research interest is in survival analysis and generalization of survival data.  
Dr. Davis, at 20% effort for all three years, will be charged throughout the duration of this project with synthesizing data obtained 
from our various forms of evaluation. He will do analysis of the results of two different surveys twice yearly and will also analyze data on 
naloxone utilization and overdose death figures annually. Additionally, he will help Dr. Jefferson by lending his expertise to the statistical 
analysis portion of the publication.  
Field Educator, Dr. Angel Dumott Schunard (40%, 4.8 months, Years 1-3) – Dr. Schunard is an Associate Professor of Social 
Work within the Sociology, Social Work, and Criminology department at Morehead State University. She earned her MSW and PhD at 
the University of Kentucky. Dr. Schnuard’s areas of interest are: substance use/abuse, criminal justice system involvement, and 
treatment-seeking behaviors. She has published in peer-reviewed journals on topics including: substance use/abuse, intimate partner 
violence, and pregnancy. She is currently the PI for multiple evaluation projects examining outcomes associated with participation in 
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community-based substance abuse treatment services (e.g., Drug Court) funded by the Substance Abuse and Mental Health Services 
Administration Center for Substance Abuse Treatment.   
Dr. Schunard’s experience in social work and in substance abuse treatment will make her an asset for developing our brochure of 
resources to be inserted in each naloxone kit. Additionally, Dr. Schunard will assist Dr. Johnson with the development of the 
educational components of our program in local high schools and at public libraries and any materials disseminated in those programs. 
These activities will take an anticipated annual 40% effort. 
Research Assistant, Benjamin Coffin III – Mr. Coffin is a Doctor of Osteopathy student at the Kentucky College of Osteopathy in 
Pikeville. Mr. Coffin has a particular interest in addiction medicine and has been involved in research projects on campus studying the 
variance in dosage leading to overdose events using morphine in rats.  
Mr. Coffin’s proximity to the area compared to the rest of the staff will make him essential for quick response to emergent situations. 
His main role will be in compiling data on prescription naloxone dispensing at each of the local pharmacies by looking at monthly 
dispensing snapshots to ensure that the program is functioning at the desired level of operation. By making those analyses monthly, Mr. 
Coffin will be able to see areas for improvement much more quickly and any necessary changes regarding recruitment or advertising 
could be implemented at sites showing need for improvement. Mr. Coffin will not receive a salary, but wages at a level of $15 per hour, 
20 hours per week, for 50 weeks of the year. 
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B. Fringe Benefits 
 
  Year One Year Two Year Three 
Project Member Position Fringe  
Requested 
Fringe 
Requested 
Fringe 
Requested 
Dr. Joanne Jefferson Principal Investigator $5,549 $5,839 $6,261 
Dr. Maureen Johnson Project Director $28,807 $30,326 $32,548 
Dr. Mimi Marquez Project Co-
Coordinator 
$11,198 $11,803 $12,698 
Dr. Roger Davis Data Analyst $4,699 $4,932 $5,266 
Dr. Angel Dumott 
Schunard 
Field Educator $10,248 $10,771 $11,526 
Benjamin Coffin III Research Assistant $6,328 $6,328 $6,328 
 
Annual Totals $66,829 $69,999 $74,627 
 
Total, Fringe Benefits: $211,455 
 
Personnel fringe costs were based on the following benefits schedule, which can also be found at 
http://www.research.uky.edu/ospa/info.html. Fringe benefits are escalated as described in the link.  Fringe benefits are requested as 
prorated based on the percentage of salary/wage support requested, as described above. 	
 
C. Naloxone Kits 
 
 
 
Contents Annual Cost 
  
Evzio® Auto-injector, 1 $330,750 
CPR Mask, 1 $17,482 
Latex Gloves, 1 pair $139 
Alcohol Swabs, 2 $24 
  
Total Kit Cost $348,395 
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Total, Naloxone Kits: $1,045,185 
 
Each naloxone kit will contain one Evzio® auto-injector, one CPR mask, one pair of latex gloves, and two alcohol swabs. 1,350 kits 
will be dispensed annually, with a per kit cost of: $245, Evzio®; $12.95, CPR mask; $0.10 one pair of latex gloves; $0.02 two alcohol 
swabs. The kit will additionally contain paper literature, which is included in the supply budget. 
While other forms of naloxone were about half the price of Evzio®, Kaléo Pharmaceuticals has given the program a bulk-buy 
discount. We also think the benefits of the auto-injectors in helping reducing stress and ensure proper administration during an 
overdose situation is a critical component to analyze when assessing the cost of the product. 
 
 
D. Equipment and Supplies 
 
 
Items Requested Year One Cost Year Two Cost Year Three Cost 
    
Laptop Computer $2,000   
Office Supplies $2,000 $2,000 $2,000 
    
Total Cost $4,000 $2,000 $2,000 
 
 
Total, Equipment and Supplies: $8,000 
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Computer laptop for Project Coordinator: $2,000, year one only. Because many hours of the week will be spent on the road and in 
the field, the Project Director requests a reliable laptop that will be able to obtain strong signals in disadvantageous locations and will 
also make it easier for her to synthesize data from multiple outreach points.  
Office Supplies: $2,000 annually. Supplies are needed to create the literature that is distributed with each naloxone kit and will also 
be needed on the ground at each pharmacy for maintenance of proper dispensing logs. These supplies include: copy paper, printer 
paper, printer cartridges, binders, tabs, Ziploc® bags.  
 
 
E. Travel 
 
 Year One Year Two  Year Three 
    
Mileage $21,664 $21,664 $21,664 
Overnights $2,000 $2,000 $2,000 
Conferences  $10,000 $10,000 
    
Annual Totals $23,664 $33,664 $33,664 
 
 
Total, Travel: $90,992 
 
 
In-state travel: Project Director to travel to intervention counties from Frankfort, Kentucky twice weekly for the duration of the 
grant. 38,688 miles annually traveled, 116,064 miles traveled over the duration of the grant, at $0.56 federal mileage reimbursement 
rate; total $64,996. Additionally, up to twenty overnight stays in the region for the Project Director annually at $100 a night when leading 
the education programs at schools in lieu of an additional weekly trip to the intervention area. 
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Out-of-state travel: Project Director to attend the American Pharmacists Association (APhA) Annual Meetings in Atlanta, 
Georgia. Budget for airfare, four nights in a hotel room, and per diem while attending the meeting. 
 
 
F. Other 
 
 
 Year One Year Two Year Three 
    
Evaluation Surveys $15,000 $15,000 $15,000 
Pharmacy Incentives $25,000 $25,000 $25,000 
Community Advertising $15,000 $10,000 $5,000 
    
Annual Totals $55,000 $50,000 $45,000 
 
 
Total, Other: $150,000 
 
 
 Evaluation surveys will be administered twice annually. One will target the attitudes of pharmacy staff on implementation and 
thus only around one hundred people with each administration. The other will target 25,000 community members (5,000 in each county) 
with each administration. In order to produce and administer these surveys, which will help to make changes as quickly as possible to 
program implementation, we will need to cover the cost of administration. We expect this cost to be $7,500 each time the surveys are 
administered, at a cost of $15,000 annually.  
 
 Pharmacy incentives will be provided at an annual rate of $5,000 for each of the five pharmacies implementing our program. This 
is because as our daily implementation staff, they will be adding this project to their already busy workload. To compensate them, this 
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will be given to the pharmacy manager annually and they can use it however they see fit to better serve their general patient population 
and the participants in this program. 
 
 Community advertising will be especially key in the first year of the program, tapering off as the program progresses but with still 
meaningful and impactful advertising. The first year of advertising created will be high quality and we will collaborate with our 
community partners in order to reach as many people as possible. These advertisements will focus mainly on the existence of the 
program. Gradually funding will decrease and an emphasis in advertising the successes of the program will be a key focus will begin to 
supplant general program knowledge advertisement. 
